In our next study, we will further investigate whether the targeted inhibition of PHLDB2 in combination with a PD-1 monoclonal antibody improves clinical outcomes in patients with head and neck squamous cell carcinoma. The gene discussed is PHLDB2; the disease is head and neck squamous cell carcinoma.